Dyne Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. We're going to get started with the next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies, and it's my pleasure to have the Dyne team with me. To my direct right is John Cox, CEO, and to his right is Erick Lucera, CFO. Welcome, both of you. Thank you.
So maybe give us an introduction about Dyne, first and foremost, what your differentiation is, what you're trying to achieve, milestones over the next 3-12 months could also be helpful.
Yeah. Thank you. And thanks for having us, Andrew. Well, 2026 has been one incredible year for this company, a transforming year for the company, in terms of clinical progress, regulatory progress, and essentially building the kind of scale and infrastructure we need to transform certain markets next year, DMD being the first that we expect to launch our first product in. Getting back to what we're trying to do and accomplish as a company, this company was founded on the notion that in neuromuscular genetic disorders, the elegant nucleotide or nucleic acid sequences are known. But maybe one of the biggest biotech hurdles or challenges has been how to deliver those nucleic acids in sufficient quantity broadly and deeply enough to tissue.
This company developed a platform that we call the FORCE platform to do that. I think our scientists have overcome what is one of the biggest biotech challenges. We demonstrated that at the end of last year in two very difficult diseases, DMD and myotonic dystrophy type 1. In both of those diseases, we showed clinically in humans using the same delivery platform that we were able to generate functional improvement across multiple efficacy measures, not slowing of decline, but actual improvement from baseline. That's never been seen before. It's a remarkable accomplishment. We went into this year thinking deeply about our capital allocation strategy for our shareholders. It's good to have Eric here, and he can talk about that some more.
That strategy was to make sure we're investing in regulatory and regulatory execution, clinical and clinical execution across multiple trials and late-stage trials, and to build out our commercial organization to prepare ourselves to be able to launch these products ourselves in the U.S. That's going to be happening, we believe, beginning next year in Q1. We also have some very important data in DM1 that I'm sure you're going to want to talk about that we expect to turn over, registrational endpoint data that we expect to turn over in Q1 of this year as well, this coming year.
Perfect. Maybe this time around, I would love to ask on DM1 first for the Q1 readout. To start off, the elephant in the room is Novartis did fail recently on their own phase III. On one hand, what's interesting is Novartis still sees a path forward. On one hand, I think you guys could be the first mover. On the other hand, the primary endpoint for your own pivotal study for Accelerated Approval is also V-HOT. Can you reassure investors why you guys will show stat sig on V-HOT?
Yeah, I'm happy to. First of all, I think everybody was disappointed in the Novartis result. I think it was unfortunate for the field and for the patients. We were surprised because the endpoint that you're referring to, video hand opening time, which is a reflection of myotonia, is an endpoint that moves very easily. I think everybody expected that to be easy to hit as long as you had a dose that was generating sufficient splicing correction. I just remind people that the core kind of pathobiology of this disease is it is a splicing or mis-splicing issue occurring in the nucleus of the cell throughout most of the cells of the body. You have to have a dose that's engaging in the nucleus.
I say that because our product, which gets to your question why we still believe, is that our product uses a very different payload than the Novartis drug. We use an antisense oligonucleotide. We use that intentionally because it is designed to get to the nucleus where the core issue is. We have demonstrated very clearly splicing correction through our dose escalation and at our highest dose, and sufficient splicing correction not only to correct or improve on VHOT and hand myotonia, but on a variety of even more important functional measures. I will just add that for us, VHOT is an endpoint that we are using as an intermediate clinical endpoint, not as a phase III endpoint. It is being used as an intermediate clinical endpoint for Accelerated Approval. It is an early indicator.
Frankly, it is not that clinically meaningful, but it is an early indicator of other functional benefit of which we need to show trends for Accelerated Approval. So, we have looked at the stats. We have 71 patients in this registrational expansion cohort, and we believe we will be stat sig on VHOT. We think we will be statistically significant on splicing correction, and we also believe that we should see trends in multiple functional measures that really matter to this community.
Got it. Thank you. I suspect, I do not know the answer, Novartis, for them to move forward and mentioning, it sounds like they saw hints of efficacy in other endpoints outside of VHOT. I suspect that the placebo for VHOT was a bit noisy. Again, I do not know. It begs the question- Did you guys factor in a placebo response? In terms of trial execution, how have you tried to curb for a placebo response?
I do not think like you. I am just hearing about what may have happened with the Novartis. It is all speculation. Hopefully, there will be some data presented at an upcoming conference. I think they have indicated they would do that. I will just tell you how we have handled it from a VHOT standpoint. First of all, we saw VHOT improve at our lowest dose of 1.8 mg per kg. Not the dose we are using for registration, but 1.8 mg per kg. We went all the way up to 6.8 mg per kg, so we know we are well above where we need to be for pharmacological activity. In terms of our placebo studies, as we have done that work with our multi-center dose, I think we had 14 placebo patients. We saw there is, of course, variability from patient to patient.
The key is that you don't have variability within the patient, or for that given patient. But what we saw with the placebo is that we saw a slight worsening of placebo of about 0.4 seconds. That's pretty consistent with natural history, and there's plenty of papers. I think there's a paper out recently by Loewenberg, really on VHOT, talking about the stability of VHOT over time for a given patient. So, I think the idea of random placebo issues is really a matter of conducting the test in a rigorous way, and we've been doing that. We have put a tremendous amount of effort through our studies on how we do the testing, the training by master physical therapists on how the test should be done for each site.
We have the same physical therapist with that patient through the testing periods, so you don't have kind of tester variability, and I could go on. We take duplicates. So, the key here is to make sure that you are getting an accurate, truthful baseline number when you do it, and I think we've taken the right steps to make sure that happens.
Thanks. Speaking of the baseline, you recently shared the baseline scores of VHOT for your pivotal cohort that reads out in Q1. So, what's the take-home message there, and do the values there make you more confident that this upcoming study will succeed?
Well, I think they do. I'll tell you the intent of that work. Listen, we had anticipated that at World Muscle, that Novartis would be presenting data for 12-month data. They would pass on VHOT, and that we would get to see what they were getting on some of the other functional measures at 12 months. What we were trying to do most recently was put together a cohort of 25 patients and present that data in terms of the functional measures at 12 months, so you could compare. But we also provided six-month VHOT data. We also provided, as you said, the baseline mean data for VHOT for the registrational expansion cohort of 71 patients. If you start comparing those baseline kind of means, they're comparable across the MAD, across that summed-up group of cohorts that we had of 25 patients, and with the 71 patients.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
